TICKERNERD
Menu
DRMADRMAHealthcare · Biotechnology

DRMA Stock Forecast: Dermata Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$0.79
−6.09% on the day

The 1 Wall Street analysts covering Dermata Therapeutics, Inc. hold a median 12-month price target of $4 — +406.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$3.8M
Ticker Nerd rank
33/ 100
Median analyst target
$4.00
Analysts covering
1
Revenue$0.0
Operating income−$3.0M
Net income−$3.0M
Free cash flow−$2.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.1%
1M
−28.2%
YTD
−66.0%
1Y
−77.0%
From 52W high
−77.0%
From 52W low
+19.1%
$0.66
$3.43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DRMA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Dermata Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
33/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Revisions
77
Growth
50
Accruals
50
Volatility
32
Momentum
31
Issuance
24
Value
11
Quality
6

Size (96): Smaller than most of the companies we track.

Quality (6): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DRMA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DRMA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26DRMAHigh $4.00Median $4.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $4.00Median $4.00High $4.00

The green dot is the last close — the median target sits +406.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2025Maxim GroupMaintainsBuy$30 → $10
21 May 2025Maxim GroupMaintainsBuy—
21 Aug 2024Maxim GroupMaintainsBuy—
23 Mar 2023Maxim GroupMaintainsBuy—
21 Sept 2021Brookline CapitalInitiatesBuy$14
14 Sept 2021Maxim GroupInitiatesBuy$9.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

DRMA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DRMA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Dermata Therapeutics, Inc. returned −77.0% against +12.4% for the S&P 500, dividends included.

DRMA vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26DRMAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DRMA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Dermata Therapeutics, Inc. (DRMA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 73% of US stocks

EV / EBITDA
0.2×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−183.9%

Higher than 8% of US stocks

Return on assets
−89.9%

Higher than 3% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Dermata Therapeutics, Inc. (DRMA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Dermata Therapeutics, Inc. has a market value of $3.8M and an enterprise value of −$1.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$8.4M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.1M.

  • Shares outstanding: 4.0M.

  • Trailing P/E: 0.1×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Dermata Therapeutics, Inc. employs 9 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

DRMA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DRMADermata Therapeutics, Inc.$3.8M33
LIMNLiminatus Pharma, Inc.$3.8M11
NRSNNeurosense Therapeutics Ltd.$3.8M3
JAGXJaguar Health, Inc.$3.8M63
CRISCuris, Inc.$4.0M39
CVKDCadrenal Therapeutics, Inc.$3.5M38
CELZCreative Medical Technology Holdings, Inc.$4.3M21

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Dermata Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DRMA news & analysis

Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment

Accesswire · 15 Oct 2026positive

Dermata Therapeutics reported positive topline results from a cosmetic study of its once-weekly Tome Foundational Treatment. The company said the treatment improved key measures of skin appearance after four treatments, and more than 71% of participants were graded as having overall skin improvements after one treatment.

Why it matters — The study results provide an update on Dermata’s recently launched skin-renewal treatment, which is available through one-time and subscription purchases.

Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

Accesswire · 25 Aug 2026positive

Dermata Therapeutics announced the commercial launch of its Tome Foundational Treatment, a once-weekly skincare product powered by Bioneedle™, now available for purchase at tomeskincare.com either as a one-month kit or via a discounted monthly subscription.

Why it matters — This marks the first product available for purchase under Dermata's new Tome skincare brand, signalling the company's entry into commercial consumer sales.

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

Accesswire · 21 Aug 2026positive

Dermata Therapeutics announced that preorders for its first direct-to-consumer skincare product, Tome Foundational Treatment, a once-weekly topical mask, are now open at www.tomeskincare.com. The company expects to begin shipping orders on August 25, 2026, ahead of the product's commercial launch.

Why it matters — A DRMA watcher would care because this marks the commercial launch of the company's first direct-to-consumer skincare product, a key milestone in expanding Dermata's market presence beyond its therapeutic pipeline.

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Accesswire · 17 Aug 2026neutral

Dermata Therapeutics announced it has entered into definitive agreements for a private placement priced at-the-market under Nasdaq rules, selling approximately 2,293,608 shares of common stock (or pre-funded warrants) with series E and series F warrants at a purchase price of $1.46 per share. The company expects $3.4 million upfront, with up to about $6.7 million in additional gross proceeds if all warrants are exercised in full.

Why it matters — This financing could provide Dermata with additional capital to fund its operations, and the potential full exercise of the warrants could bring further proceeds to the company.

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Accesswire · 11 Aug 2026positive

Dermata Therapeutics provided a corporate update and reported financial results for the second quarter ended June 30, 2026. The company announced the expected August 25, 2026 launch of its first commercial product, Tome™ Foundational Treatment, and noted it recently introduced the Tome brand at a beauty and wellness show in Las Vegas.

Why it matters — The announcement marks Dermata's transition toward a commercial-stage, direct-to-consumer skincare company with a firm launch date for its first product, a key development for DRMA watchers.

FAQ

Frequently asked questions about DRMA stock

What is the DRMA stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Dermata Therapeutics, Inc. have a median 12-month price target of $4, with estimates ranging from $4 to $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DRMA stock a buy right now?

Of the 1 analysts covering Dermata Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Dermata Therapeutics, Inc. 33 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DRMA?

As at 31 Oct 2026, Dermata Therapeutics, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

Will DRMA stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +406.5% from the last close, and Ticker Nerd's factor model ranks Dermata Therapeutics, Inc. 33 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DRMA stock forecast for 2030?

No analyst covering Dermata Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.

How has DRMA stock performed over the past year?

Dermata Therapeutics, Inc. returned -77.0% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Dermata Therapeutics, Inc. do?

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on developing and commercializing products for medical and aesthetic skin conditions.

What is the latest news on DRMA?

The most recent item we track (Accesswire, 15 Oct 2026): "Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment". Dermata Therapeutics reported positive topline results from a cosmetic study of its once-weekly Tome Foundational Treatment. The company said the treatment improved key measures of skin appearance after four treatments, and more than 71% of participants were graded as having overall skin improvements after one treatment.

Company

About Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company focused on developing and commercializing products for medical and aesthetic skin conditions. The company currently works on topical dermatologic solutions that leverage its proprietary technology platform to target a range of skin disorders and cosmetic applications. Its product pipeline includes treatments designed for conditions such as acne, psoriasis, rosacea, and hyperhidrosis, as well as needle-free intradermal delivery approaches for aesthetic uses. Dermata Therapeutics also operates in the direct-to-consumer skincare market through the Tome brand, reflecting its broader emphasis on skin renewal and everyday dermatologic care. Headquartered in San Diego, California, Dermata Therapeutics serves as a specialized participant in the dermatology market, combining pharmaceutical development with consumer skincare products aimed at skin health and appearance.

CEO Mr. Gerald T. Proehl · 9 employees · United States · https://www.dermatarx.com